This study investigates whether experimental diabetes alters the ease with which platelet aggregation can be initiated in pial and mesenteric mlcrovessels of the mouse. Aggregation was elicited by exposing mlcrovessels to radiant energy from a mercury lamp in the presence of sodium fluoresceln. The time required for this noxious stimulus to Initiate aggregation was similar In fed or fasted alloxan diabetics and their controls, and in fed streptozotocin diabetics and their controls, but was significantly shortened in streptozotocin mice fasted for 18 to 24 hours when these animals were compared with either fed or fasted controls. Aggregation was also elicited by puncture of mlcrovessels or by mlcropuncture plus locally applied adenosine 5'-dlphosphate. No differences in aggregablllty were found between either fed or fasted diabetics and their respective controls. In the light plus dye model of Injury, the capacity to enhance aggregation at will by fasting streptozotocin diabetics may provide a means by which some of the factors controlling aggregation In this model of diabetes can be identified, and this in turn may provide Insights Into the reasons for the variable occurrence of enhanced aggregation in other species or In other types of diabetes.
P latelet aggregation in diabetes is of interest for many reasons, including the possible relationship between aggregation and enhanced atherosclerosis in diabetics. There are many reports of enhanced platelet aggregation in diabetic humans, but this phenomenon has not been observed in all studies or in all groups of diabetics. 1 " 7 Moreover, the variables responsible for the presence or absence of enhanced aggregation have not been determined, although an increased production of thromboxane A 2 by diabetic platelets has been suggested as a possible cause of increased aggregability. 78 All studies of platelets from human diabetic subjects have utilized in vitro tests of aggregation. To gain insight into the factors determining aggregability of human diabetic platelets, in vitro studies of rat platelets have also been performed. Unlike the situation in humans, diabetic rat platelets have shown reduced rather than enhanced aggregability when suspended in diabetic plasma.
9
' 10 When tested in the absence of the plasma factor, however, they showed enhanced aggregation. 910 The relevance of these in vitro observations to in vivo phenomena has not been established, and in vivo studies of platelet aggregation in diabetic animals have been limited. 11 " 13 These few published studies indicate enhanced aggregability in microvessels on the cerebral surface (pial vessels) of the rabbit.
The following report describes our in vivo findings in diabetic mice. We demonstrate that fasting enhances platelet aggregation in pial and mesenteric microvessels of mice rendered diabetic with streptozotocin.
14 Fed streptozotocin mice failed to display abnormal platelet aggregability. Fasting streptozotocin mice displayed 127 enhanced aggregation whether they were compared with fasted or fed nondiabetic controls. These observations could not be duplicated in mice rendered diabetic with alloxan 14 rather than streptozotocin. Furthermore, enhanced aggregation in fasted streptozotocin mice could only be demonstrated with one method of inducing platelet aggregation, but not with another.
Methods

Animals
Male mice, ICR strain, were anesthetized with urethane, and a tracheotomy performed. This was followed either by a craniotomy with exposure of the pial vessels 15 or by a linear abdominal incision through which a loop of intestine was extruded and draped over a pedestal.
16
Microvascular observation began approximately 15 minutes after induction of anesthesia. After preliminary observations with a dissecting microscope, the pial or mesenteric vessels were observed with a Leitz Ultropak microscope equipped with a "dipping cone" (immersion attachment). Observations were made with a tungsten lamp except during production of aggregates when a mercury lamp was used. A dual lamp housing permitted instantaneous shifting between the tungsten and mercury light source.
Induction of Aggregation
Two techniques were used. The first employed light plus dye and has been described extensively in previous publications.
17
" 19 Briefly, light from an appropriately filtered mercury lamp injures vascular endothelium if, and only if, an intravenous energy-absorbing target such as sodium fluorescein is circulating. 17 We selected a single field containing an arteriole and venule for continuous microscopic observation. We then injected 0.2 ml of 2% sodium fluorescein into the tail vein and immediately exposed the field, via the Ultropak optical system, to the incident rays from the mercury lamp. We measured the time elapsing from the onset of this noxious stimulus to the appearance of the first platelet aggregate, recognized microscopically as a fluorescent mass adherent to the endothelium.
1718 Control values differed widely from one time period to another, precluding comparisons between the control and experimental groups studied at different times. We do not know what factors determined the variability, but it appeared in other in vivo models of platelet aggregation or clot formation and was indicated by standard deviations exceeding the mean value of the parameter being measured.
20 " 22 For this reason, we continued to follow our initial design, 1718 which entailed examining a control animal immediately before or after an experimental (diabetic) mouse, so that uncontrolled factors present over any period of time were randomly distributed between the two groups.
The second technique for inducing aggregation employed injury with a micropipette and exposure of the vessel to adenosine 5'-diphosphate (ADP). A micropipette puller was used to produce a glass micropipette with a tip approximately 2 ^ in diameter. With the aid of a micromanipulator and dissecting microscope, a vessel was punctured just once with the pipette, and the animal was transferred in a few seconds to the stage of the Leitz Ultropak for further observation. If no platelet aggregate ("white body") appeared at the puncture site, the entire microscopic field was covered with a drop of ADP beginning with 0.086 ^M, and platelet aggregates were again sought. ADP was used because local application to microvessels either in the absence of or following injury is known to produce platelet aggregation and because ADP is a substance that is released from platelets and thought to play an important role in stimulating platelet aggregation during nonexperimental situations.
11 " 132324 The drop of ADP was held between the tip of the immersion lens ("dipping cone") and the tissue. If no aggregate appeared within 3 minutes, the drop was replaced by one with a higher concentration of ADP (0.86 ^M) and observation was continued for another 3 minutes. If no aggregates appeared, 8.6 ^M ADP was used, and in studies of mesenteric vessels (but not of brain vessels), if 8.6 nM ADP was ineffective, 86 ^M ADP was used. If aggregates appeared either after puncture alone or following puncture plus addition of ADP, we measured the latency between the initiating stimulus and first aggregate and counted the number of emboli breaking off the aggregate over a 6-minute period following aggregation. In addition, we recorded whether aggregation was produced by puncture alone, whether ADP was required, and if so what concentration was sufficient to induce aggregation after puncture. We also recorded failure to produce aggregation even after ADP. In any mouse only a single arteriole or venule was punctured. When produced either by puncture or puncture plus ADP, aggregates almost always occurred at the puncture site but sometimes were a small distance from the site (e.g., 40 â way). If ADP was required, additional aggregates might appear at other sites or even in other vessels, particularly venules. However, only the aggregate at or next to the puncture site was used in compiling our data. It seemed unlikely that aggregates were only coincidentally located at the puncture sites and were related instead to nonspecific factors such as operative trauma.
Nevertheless, to rule this out, every field was observed in the presence of 8.6 /uM ADP prior to puncture. Any vessel displaying aggregates under these circumstances was discarded.
Production of Diabetes
Two well-known techniques were used 14 employing intraperitoneal injection of alloxan (100 mg/kg) or of streptozotocin (200 mg/kg). These agents destroy pancreatic beta cells, producing an insulin-deficient model of diabetes. 14 All animals used had sufficient hyperglycemiato produce glycosuria as determined with Combistix (Ames Laboratories, Elkhart, Indiana).
Measurement of Blood Glucose, Llplds, and Insulin
Plasma glucose measurements were made on tail vein blood using a glucose oxidase technique modified for use in mice.
25 Plasma cholesterol, triglycerides, and fatty acids were measured by thin layer chromatography as previously described.
28 Plasma insulin was determined by radioimmunoassay using an 125 I insulin kit (Immuno Nuclear Corporation, Stillwater, Minnesota) modified to use 50 /x\ plasma samples. Table 1 summarizes the data from one study of pial arterioles in fed mice and two studies of mesenteric arterioles in fed mice. In no study did streptozotocin diabetes in fed mice influence the time required to initiate aggregation. Table 1 also illustrates the effect of streptozotocin diabetes in four studies of fasted mice. In the three studies of pial vessels and the one study of mesenteric vessels, streptozotocin diabetics displayed enhanced platelet aggregation, as indicated by a significant shortening of the time required by the noxious stimulus to initiate aggregation (p < 0.05 in each study, Mann Whitney Test). 27 The fasted mice were without food for 18 to 24 hours but received water ad libitum.
Results
Platelet Aggregation In Plal and Mesenterlc Vessels Induced by Light plus Dye
Streptozotocin Diabetes
Because the preceding data showed an effect of streptozotocin only in studies of fasted mice, we carried out an additional investigation in which fed and fasted mice were examined at the same time. Animals had diabetes for 7 to 9 weeks. On each day, four mice were observed: a fed diabetic, a fed control, a fasted diabetic, and (10) 'Number in parentheses indicates the number of mice in each group. a fasted control. Again, a significant reduction in the time to initiate aggregation was found only in the fasted streptozotocin diabetics (fed diabetic, 98 ± 66 seconds; fed control, 114 ± 41 seconds; fasted diabetic, 40 ± 11 seconds; fasted control, 158 ± 125 seconds; M ± SD, Kruskal-Wallace analysis of variance, p < 0.01; fasted diabetic less ihan each of the other groups, p < 0.05, Mann Whitney Test).
27
Alloxan Diabetes
As shown in table 2, platelet aggregation in alloxan diabetics was not different from that of age-matched controls. This was true whether animals were fed or fasted, and whether aggregation was monitored in pial or mesenteric arterioles (Mann-Whitney test, all p >0.05).
27
Platelet Aggregation In Pial and Mesenteric Vessels Induced by Puncture and ADP
As indicated under Methods, we asked the following questions: Was puncture alone sufficient to induce aggregation or was ADP required? If ADP was required, what was the threshold dose producing aggregation? Did any mice fail to display aggregation even after the highest dose of ADP? How many seconds elapsed between application of an effective stimulus and aggregation? What was the frequency of embolization from aggregates? We were not able to detect any significant differences between alloxan diabetics and their controls or between streptozotocin animals and their controls in studies of animals that were diabetic for 1 to 11 weeks.
Sixteen studies were performed, eight with alloxan and eight with streptozotocin mice. Each study utilized 10 diabetics and 10 age-matched controls. In alloxan diabetes, pial arterioles were observed in two studies (one of fasted mice and one of fed mice), pial venules were observed in two studies (one of fasted, one of fed mice), and four studies of mesenteric vessels were carried out paralleling the four studies of pial vessels. An identical series of eight investigations was performed utilizing the streptozotocin animals.
Since no differences were found between the diabetics and controls, we show only four representative studies in table 3. To simplify the display we show only whether aggregation was finally produced, but do not show whether it was produced by puncture alone or only after the addition of ADP. We have also omitted the tabulation of the threshold doses required to elicit aggregation in those animals where ADP was used. The incidence of aggregation in diabetes and controls was compared in each study using the Fisher Test of Exact Probability; the latency of aggregation and numbers of emboli were analyzed with the Mann-Whitney Test. 27 No effect of diabetes was observed on these parameters.
Glucose, Llpld, and Insulin Levels
The plasma glucose and lipid levels of representative groups of mice diabetic for 5 to 10 weeks are shown in table 4 together with those of age-matched controls. Each fed animal also was studied in the fasted state. The insulin values for 10 fasted alloxan mice were 5.3 ± 3.4 /nU/ml (M ± SD), and for ten fasted streptozotocin mice, 5.6 ± 3 . 8 M U / I T I I . Streptozotocin (n = 10) 460 ± 56* 232 ±133 114 ±15 102 ±27 36 ±16* 9 ± 5 (mg%) Control (n = 10) 133 ±11* 103 ±13 92 ± 35* 87 ± 13 32 ± 10 30 ± 14 (mg%) Alloxan (n = 10) 550 ±51* 444 ± 106 86 ± 22 81 ± 20 43 ± 7* 11 ± 8 67 ± 40* 10 ±11 (mg%) *p < 0.05, paired t test, fed vs fasting. All data expressed as mg %.
Discussion
We were able to demonstrate enhanced aggregation of platelets in vivo in mice with streptozotocin-induced diabetes only by depriving them of food for 18 to 24 hours. We were not able to demonstrate enhanced aggregation in mice with alloxan diabetes, even in fasted animals. Moreover, the enhancing effect of fasting on aggregation in streptozotocin mice could only be demonstrated when microvessels were injured by radiant energy, not by mechanical puncture or puncture plus ADP.
We have no explanation for our results. We could not relate differences in the effect of fasting on streptozotocin and alloxan mice to differences in glucose, triglyceride, or free fatty acid levels since these levels were similarly diminished after fasting in both types of diabetes. Nor could we relate the results of fasting to an effect on insulin levels since the insulin levels were the same in fasted streptozotocin and fasted alloxan groups.
The results are interesting for several reasons. First, they deal With platelet aggregation in vivo, an area in which there are relatively few studies of diabetic animals. 11 " 13 While in vivo studies may not distinguish between differences in platelet adhesiveness and differences in the capacity of platelets to undergo the release reaction or to aggregate, such studies are generally interpreted as reflecting aggregability, at least in part, and provide unique information concerning the rapidity with which aggregates may be induced in the microcirculation.
Second, because we can control aggregation in streptozotocin mice, we may be able to gain insight into the factors regulating aggregation in this diabetic model. With respect to the effect of fasting on platelet function, it has recently been reported 28 that platelets from fasted rats have a greater uptake of arachidonic acid than control platelets. It may be that an increase in arachidonate uptake by platelets in fasted mice provides increased substrate for cyclooxygenase-dependent metabolic reactions leading to platelet aggregation. Why this should be so only in streptozotocin diabetics and not in control mice or in alloxan diabetics, and why the effect is not seen with both models of vessel injury, remains to be explained.
Our results are also of interest because they may seem at variance with often cited in vitro studies of human platelets showing enhanced aggregation in diabetics, and with in vivo studies of rabbits.
11
" 13 Of course, species differences, differences in the stimuli causing aggregation, and many other factors mandate caution in extrapolating from one animal to another or from animals to man. Nevertheless, animal models are studied in the hope of gaining insight into human disease. It is therefore appropriate to point out that many groups of human diabetics fail to show increased aggregation of platelets 2367 and that in diabetic rats, decreased rather than increased aggregability may be found in vitro if diabetic platelets are studied in the presence of diabetic plasma.
910 Thus, our failure to find enhanced aggregation in several studies of diabetic mice is not unique to that species or to a given means of inducing aggregation, and further analysis of the cause of enhanced aggregation in the fasted streptozotocin diabetic mouse, injured with light plus dye, may help us understand the factors accounting for variable aggregability in other diabetic species as well.
Finally, in discussing our data we must consider a contribution by the vessel wall itself. Diminished production of prostacyclin, an antiaggregant, has been observed in blood vessels from human diabetics 29 and from rats 30 with streptozotocin diabetes. Moreover, enhanced aggregation in fasted streptozotocin diabetics could reflect greater vascular damage in those mice compared with fed animals. However, it is difficult to understand why damage produced by light plus dye would be enhanced by fasting only in streptozotocin diabetics, or indeed, why fasting should enhance damage only when light plus dye was used but not puncture. It is equally difficult to imagine that prostacyclin synthesis by the vessel wall would be altered only in the fasted streptozotocin mouse.
